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Abstract
Background: The novel gene HA117 is a multidrug resistance (MDR) gene expressed by all-trans retinoic acid-resistant 
HL-60 cells. In the present study, we compared the multidrug resistance of the HA117 with that of the classical 
multidrug resistance gene 1 (MDR1) in breast cancer cell line 4T1.
Methods: Transduction of the breast cancer cell line 4T1 with adenoviral vectors encoding the HA117 gene and the 
green fluorescence protein gene (GFP) (Ad-GFP-HA117), the MDR1 and GFP (Ad-GFP-MDR1) or GFP (Ad-GFP) was 
respectively carried out. The transduction efficiency and the multiplicity of infection (MOI) were detected by 
fluorescence microscope and flow cytometry. The transcription of HA117 gene and MDR1 gene were detected by 
reverse transcription polymerase chain reaction (RT-PCR). Western blotting analysis was used to detect the expression 
of P-glycoprotein (P-gp) but the expression of HA117 could not be analyzed as it is a novel gene and its antibody has 
not yet been synthesized. The drug-excretion activity of HA117 and MDR1 were determined by daunorubicin (DNR) 
efflux assay. The drug sensitivities of 4T1/HA117 and 4T1/MDR1 to chemotherapeutic agents were detected by Methyl-
Thiazolyl-Tetrazolium (MTT) assay.
Results: The transducted efficiency of Ad-GFP-HA117 and Ad-GFP-MDR1 were 75%-80% when MOI was equal to 50. 
The transduction of Ad-GFP-HA117 and Ad-GFP-MDR1 could increase the expression of HA117 and MDR1. The drug 
resistance index to Adriamycin (ADM), vincristine (VCR), paclitaxel (Taxol) and bleomycin (BLM) increased to19.8050, 
9.0663, 9.7245, 3.5650 respectively for 4T1/HA117 and 24.2236, 11.0480, 11.3741, 0.9630 respectively for 4T1/MDR1 as 
compared to the control cells. There were no significant differences in drug sensitivity between 4T1/HA117 and 4T1/
MDR1 for the P-gp substrates (ADM, VCR and Taxol) (P < 0.05), while the difference between them for P-gp non-
substrate (BLM) was statistically significant (P < 0.05). DNR efflux assay confirmed that the multidrug resistance 
mechanism of HA117 might not be similar to that of MDR1.
Conclusions: These results confirm that HA117 is a strong MDR gene in both HL-60 and 4T1 cells. Furthermore, our 
results indicate that the MDR mechanism of the HA117 gene may not be similar to that of MDR1.
Introduction
Multidrug resistance (MDR) is a major cause of treatment
failure and mortality in cancer patients. Breast cancer is
the most prevalent cancer among women and the second
leading cause of death in cancer. The most widely used
treatment of breast cancer is chemotherapy, while the
success of chemotherapy in breast cancer patients is also
seriously limited by the development of MDR [1]. One
well-known mechanism of MDR is the over-expression of
ATP-binding cassette transpo r t e r s  s u c h  a s  m u l t i d r u g
resistance gene 1 (MDR1), multidrug resistance-associ-
ated protein 1 (MRP1), lung resistance protein (LRP) and
the breast cancer resistance protein (BCRP) [2-7]. P-gly-
coprotein (P-gp), which is encoded by the MDR1, is the
most extensively studied drug transporter. It is an integral
membrane glycoprotein with a molecular mass of 170
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kDa and has been postulated to function as a pump that
removes hydrophobic anticancer agents from drug-resis-
tant cells, thus promoting MDR [8]. The novel gene
HA117 (Gene Bank accession number: AY230154), which
was screened and cloned from the ATRA-resistant acute
myeloid leukemia cell line HL-60/ATRA using differen-
tial hybridization and gene chip assays [9], was shown to
promote MDR in the chronic myelogenous myeloid leu-
kemia cell line K562 [10]. However, the strength and
mechanism of the MDR of HA117 have not yet been elu-
cidated, especially in solid tumor cells. Our aim in the
current study was to compare the MDR strength of
HA117 to that of MDR1 and to examine the possible
MDR mechanism(s) of HA117 in breast cancer cell line
4T1 which is a classical representation of solid tumor cell
line.
Our results suggest that HA117 is a strong MDR gene
and that its MDR index is similar to that of MDR1 for P-
gp substrate drugs and much higher than that of MDR1
for P-gp non-substrate drugs. In addition, using the
breast cancer cell line, we show that the MDR mechanism
of HA117 may not be similar to that of MDR1. As such,
further studies need to be conducted to determine the
mechanism of HA117 to promote MDR.
Materials and methods
Cell culture
The HEK 293 cell line was a generous gift from professor
Tong-Chuan He (Laboratory of Molecular Oncology,
University of Chicago, USA). The breast cancer cell line
4T1 was bought (ATCC, USA) and preserved in our labo-
ratory. The cells were maintained in Dulbecco's Modified
Eagle Medium/Nutrient Mixture F-12 (DMEM/F12)
(Gibco, USA) supplemented with 10% fetal bovine serum
(FBS, Gibco, USA) and RPMI-1640 medium (Gibco,
USA) supplemented with 10% FBS (Gibco, USA), respec-
tively at 37°C in a humidified atmosphere of 5% CO2. The
cells were passaged approximately once every 3 days.
Preparation of high titer adenovirus vector supernatant
Recombinant adenoviral vectors expressing green fluo-
rescence protein (GFP) and HA117 (Ad-GFP-HA117),
GFP and MDR1 (Ad-GFP-MDR1) or only GFP (Ad-GFP)
were previously constructed in our laboratory [10]. HEK
293 cells were transducted with Ad-GFP-HA117, Ad-
GFP-MDR1 or Ad-GFP viral supernatant at a multiplicity
of infection (MOI) of 2-5. When all the cells exhibited a
round morphology and approximately 80% of them were
detached from the culture flask (usually 4 to 5 d post-
transduction), the cells were harvested and combined.
The cells were then frozen using a dry ice/methanol bath,
immediately thawed in a 37°C water bath, and vortexed.
A total of 4 freeze/thaw/vortex cycles were performed.
After expanding for 3 cycles and purifying using density
gradient centrifugation, the high titer recombinant aden-
oviruses Ad-GFP-HA117, Ad-GFP-MDR1 and Ad-GFP
were harvested, filtered in a aseptic conditions through a
0.45-μm filter and stored at -80°C [11].
Transduction of 4T1 cells with adenoviral vector 
supernatant
Logarithmic phase 4T1 cells were divided into 4 groups.
Cells in group 1 were transducted with Ad-GFP-HA117
and cells in group 2 were transducted with Ad-GFP-
MDR1 and served as the experimental groups. the stable
transductants of these cells in the two groups are referred
to as 4T1/HA117 and 4T1/MDR1. A third group of cells
was transducted with empty Ad-GFP and served as a
control group. the stable transductants of these cells are
referred to as 4T1/GFP. Untransducted cells served as a
blank control and are referred to as 4T1. The cells were
plated on 96-well plates at a density of 2.0 × 105 cells/well
and incubated for 16 h. The cells in experiment groups
and control group were devided into 6 subgroups and
transducted with adenoviral vector according to the fol-
lowing MOI: MOI = 1, 10, 50, 100, 500 or 1000 for each
subgroup. Each subgroup contained 6 repeated pores.
The transduction efficiency was quantified using fluores-
cence microscopy and flow cytometry 48 h after trans-
duction.
Detection of HA117 and MDR1 mRNA expression by 
reverse transcription-polymerase chain reaction (RT-PCR)
48 h after transduction, total RNA was extracted from
cells in the experiment and control groups using the
Tripure isolation reagent (TianGen Biotechnology,
China) according to the manufacturer's instructions. RT
was performed using the TaKaRa RT kit (TaKaRa Bio-
technology, China). The expression levels of mRNA were
normalized to glyceraldehyde phosphate dehydrogenase
( G A P D H ) .  T h e  r e l a t i v e  e x p r e s s i o n  l e v e l s  o f  t h e  t a r g e t
genes were determined by calculating the fluorescence
intensity ratio between the target gene and GAPDH. The
primers used for PCR were designed according to the
information from the human genomic data base and were
synthesized by Invitrogen Biotechnology Company
(USA). The sequences of the primers used for the amplifi-
cation of HA117, MDR1 and GAPDH were as follows:
HA117- (forward) 5'-CAGAGTCAGGGACTTCAGC-
CTTAT-3', (reverse) 5'-CTGTTTCCTTCTCACTCCCA-
ACCA-3'; MDR1- (forward) 5'-GCTGGTTTGA TGTG
CACGATGTTGG-3', (reverse) 5'-ATTTTGTCACCA-
ATTCCTTCATTAA-3'; GAPDH- (forward) 5'-ACCA-
CAGTCCATGCCATCACT-3', (reverse) 5'-TCCAC
CACCCTGTTGCTG TA-3. The PCR conditions were as
follows: denaturation at 94°C for 5 min and 33 cycles of
denaturation at 94°C for 30 s, annealing at 60°C for 30 s
and extension at 72°C for 1 min, and a final extension atZhao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:98
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72°C for 5 minutes. The PCR products were resolved on
2% agarose gels, and the gels were photographed. Densi-
tometric analysis was performed using the UVP gel image
analysis system (Bio-Rad, USA).
Detection of P-gp expression using a western blotting
The cells were harvested and lysed in lysis buffer (0.5%
Nonidet P-40, 10 mM Tris-HCl pH 7.4, 150 mM NaCl, 1
mM EDTA, and 1 mM Na3VO4) supplemented with pro-
tease inhibitors and 1 mM phenylmethylsulfonyl fluoride
(PMSF). Approximately 100 μg of total cellular lysate was
then subjected to standard sodium dodecyl sulfate poly-
acrylamide gel electrophoresis (SDS-PAGE). For western
blotting analysis, the proteins were transferred to polyvi-
nylidene fluoride (PVDF) membranes (Millipore Inc.,
USA), which were then blocked for 1 h with 8% non-fat
milk in 10 mM Tris-HCl pH 7.5, 100 mM NaCl, and 0.1%
(w/v) Tween 20. The membranes were first incubated
with antibodies against β-actin or P-gp (both from Santa
Cruz, USA) overnight at 4°C, followed by 1 h incubation
with horseradish peroxidase-conjugated secondary anti-
body. The protein signals were detected using an
enhanced chemiluminescence kit (BiYunTian Biotechnol-
ogy, China) and analyzed using the Bio-Rad (USA) imag-
ing system and associated software according to the
manufacturer's instructions.
Drug elimination experiments
The activities of HA117 and MDR1 were determined
using the daunorubicin (DNR) efflux assay. For this pur-
pose, 2.0 × 106 cells/ml from each group were incubated
at 37°C in an atmosphere of 5% CO2 for 30 min in RPMI-
1640 supplemented with 10% fetal calf serum (FCS) con-
taining 7.5 g/ml DNR (Sigma). After two washes, the cells
were transferred into daunomycin-free medium and
allowed to efflux for 10 min. Then 10 μg/ml of verapamil,
a P-gp inhibitor, were added to the cells to stop efflux,
and the cells were washed two times. The cells were then
analyzed by flow cytometry using a FACScan flow cytom-
eter (Becton Dickinson, San Jose, CA) at an excitation
wavelength of 488 nm and using 530/30 nm (green fluo-
rescence) bandpass filters.
Analysis of drug sensitivity using Methyl-Thiazolyl-
Tetrazolium (MTT) assay assays
To assess multidrug chemosensitivity, cells in the experi-
ment and control groups were plated on 96-well plates at
a density of 3.0 × 105 cells/well and incubated for 24 h at
37°C. After this time, the medium was removed, replaced
with fresh medium containing adriamycin (ADM; Phar-
macia Italia S.p.A, Italy), vincristine (VCR; Wanle Phar-
maceutical Factory, China), paclitaxel (Taxol; Sigma
Aldrich, USA) and bleomycin (BLM; Huayao Zhushi
Association, Japan) at varying plasma peak concentra-
tions (PPC) of 0.01 PPC, 0.1 PPC, 1.0 PPC, 10.0 PPC, and
the cells were incubated for another 48 h. Afterwards, the
cells were stained with 20 μl of 5.0 mg/ml sterile MTT
solution (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetra-
zolium bromide; Sigma) for 4 h at 37°C, after which the
medium was removed and thoroughly mixed with 100 μl
dimethyl sulfoxide (DMSO) to dissolve formazan crys-
tals. The cells were then agitated for 10 min, and their
absorbance was measured at 490 nm using a spectropho-
tometric microplate reader (Bio-Rad Inc., USA). Each
treatment group was analyzed in triplicate, and the
experiment was repeated 3 times. The inhibition ratio for
the tumor cells at each drug concentration was calculated
using the following formula: inhibition ratio (%) = (1-
average OD value of the experimental cells/average OD
value of the control cells) × 100. The half maximal inhibi-
tory concentration (IC50) of each chemotherapeutic drug
was determined from the dose-response curve con-
structed according to the inhibition ratio for each con-
centration. The resistance index (RI) for cells was
calculated using the following formula: RI = IC50 of the
experimental cells/IC50 of the control cells.
Statistical analysis
Statistical analysis was conducted using SPSS 16.0 soft-
ware. The results are presented as the mean ± standard
deviation. The ANOVA and the Student's t-test were
used to compare mean values between groups. Two-sided
probability values of less than 0.05 were considered statis-
tically significant.
Results
Production of recombinant adenoviruses in HEK 293 cells
The recombinant adenoviruses Ad-GFP-HA117, Ad-
GFP-MDR1, and Ad-GFP were transducted into HEK
293 cells. After 4-5 d, the transducted cells could be
observed floating in the media under a fluorescence
microscope (Figure. 1). The viral titers of Ad-GFP-
HA117, Ad-GFP-MDR1 and Ad-GFP ranged between
2.5-3.5 × 109 plaque forming units (PFU)/ml.
Fluorescence and adenovirus quantification in 4T1 cells
The expression of GFP in 4T1 cells was observed 48 h
after transduction using a fluorescence microscope (Fig-
ure. 2). As shown in Figure 3, the transduction efficien-
Figure 1 GFP expression in HEK 293 cells transducted with the re-
combinant adenoviruses Ad-GFP-HA117, Ad-GFP-MDR1 or Ad-
GFP (×100).Zhao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:98
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cies of individual stable transductants were between 75-
80% when the adenovirus MOI = 50. In addition, the
transduction efficiency increased with increasing con-
centration of adenovirus. Both the survival rate (over
80%) and the transduction efficiency (80%) of 4T1 cells
were relatively high when the adenovirus MOI = 50.
Thus, an MOI = 50 was used in further experiments.
Up-regulation of HA117 and MDR1 mRNA and P-gp protein 
expression in 4T1 cells
To detect changes in the mRNA and protein levels of
HA117 and MDR1 in 4T1 cells transducted with Ad-
GFP-HA117, Ad-GFP-MDR1 or Ad-GFP viral superna-
tants for 48 h and RT-PCR and western blotting analysis
were performed. However, we could not be detect
because an antibody against this protein has not been
synthesized. As shown in Figure 4, the mRNA levels of
HA117 and MDR1 were remarkably higher in 4T1/
HA117 and 4T1/MDR1 transductants than in 4T1 cells
or 4T1/GFP transductants (P < 0.01 for HA117 and P <
0.05 for MDR1). In addition, western blotting analysis
(Figure. 5) showed a corresponding increase change in P-
gp expression in the 4T1/MDR1 transductants. Collec-
tively, these results demonstrate that the expression of
HA117 or MDR1 can be effectively up-regulated by
recombinant adenovirus-mediated transduction of vec-
tors expressing the HA117 or MDR1 genes, respectively.
The HA117 gene has no drug-excretion function
To explore the multidrug resistance mechanism of
HA117 and assess whether its drug-induced activity is
the same as that of MDR1, a DNR efflux assay was carried
out to detect the DNR fluorescence intensity when 4T1
cells were transducted with the recombinant adenovi-
ruses. As shown in Figure 6, there was no significant dif-
ference in the DNR fluorescence intensity between 4T1/
HA117 and 4T1 cells (P > 0.05), whereas the difference
between 4T1/MDR1 and 4T1 cells was significant (P <
0.05).
Sensitivity to anticancer drugs
The MTT assay allowed us to determine the drug sensi-
tivities of 4T1/HA117, 4T1/MDR1, 4T1/GFP and 4T1
cells to anticancer drugs - ADM, VCR, Taxol and BLM,
which are the commonly used drugs in the therapy of
breast cancer, especially the first three. On the other
hand, ADM, VCR and Taxol are the substrates of P-gp
and BLM is a P-gp non-substrate drug, which make them
suitable to be investigated in our present study so as to
evaluate the MDR function of HA117 comparing with
that of MDR1. As shown in Table 1, both the HA117 and
Figure 4 The mRNA expression levels of the HA117 and MDR1 
genes in 4T1 cells 48 h after transduction of Ad-GFP-HA117 or Ad-
GFP-MDR1 as quantified by RT-PCR. The levels of HA117 and MDR1 
mRNA increased significantly 48 h after transduction. The expression of 
GAPDH mRNA was also examined and served as a loading control. The 
bar graphs represent the quantification and comparison of the signal 
intensity of the mRNA bands on the gel. M: 50-bp DNA ladder; 1: 4T1; 
2: 4T1/GFP transfectants; 3: 4T1/HA117 transfectants; 4: 4T1 cells; 5: 
4T1/GFP transfectants; 6: 4T1/MDR1 transfectants. P < 0.05 ** vs. con-
trol cells, P < 0.01*** vs. control cells. This experiment was repeated at 
least 3 times with the same results.
Figure 5 The expression of P-gp as assessed by western blot anal-
ysis. The levels of β-actin protein were also examined and served as a 
loading control. The expression of P-gp was upregulated in MDR1-
transfected 4T1 cells. The bar graphs represent the quantification and 
comparison of the signal intensity of the bands on the immunoblots. P 
< 0.05** vs. control cells. This experiment was repeated at least 3 times 
with the same results.
Figure 2 GFP expression in 4T1 cells 48 h after transduction. A: 
4T1 cells (×100); B: 4T1/HA117, 4T1/MDR1 or 4T1/GFP transductants 
(×100); C: 4T1 cells (×200); D: 4T1/HA117, 4T1/MDR1 or 4T1/GFP trans-
ductants (×200). We show only one figure of the all three transduc-
tants' microscope images because of the limination of length.
Figure 3 Transduction efficiency of 4T1 cells 48 h after transduc-
tion with Ad-GFP-HA117, Ad-GFP-MDR1 or Ad-GFP at a MOI = 50. 
A: Transduction efficiency of Ad-GFP-HA117 in 4T1/HA117 cells; B: 
Transduction efficiency of Ad-GFP-MDR1 in 4T1/MDR1 cells; C: Trans-
duction efficiency of Ad-GFP in 4T1/GFP cells. The number of cells is 
shown on the × axis. UR and UL indicate the cells with and without 
green fluorescence, respectively. Cells expressing GFP represent those 
that were successfully transducted. This experiment was repeated at 
least 3 times with the same results.Zhao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:98
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MDR1 transductants exhibited decreased sensitivity to
the P-gp substrate drugs ADM, VCR and Taxol (P < 0.05).
Interestingly, overexpression of HA117 also decreased
the sensitivity of the transductants to the P-gp non-sub-
strate drug BLM (P < 0.05). The IC50 and the RI of 4T1/
HA117 cells was lower than that of 4T1/MDR1 cells for
P-gp substrate drugs, but these differences were not sta-
tistically significant (P > 0.05). In contrast, the IC50 and
the RI of 4T1/HA117 cells was higher than that of 4T1/
MDR1 cells for P-gp non-substrate drugs and the differ-
ence was statistically significant (P < 0.05). This result
supported our earlier finding that 4T1/HA117 and 4T1/
MDR1 cells exhibit increased resistance to anticancer
drugs.
Discussion
MDR is a phenomenon whereby tumor cells exposed to
one cytotoxic agent develop cross-resistance to a range of
structurally and functionally unrelated compounds. The
exact mechanism of MDR in cancer cells is still under
investigation, but many MDR-associated genes have been
identified, as mentioned earlier [2-7]. The MDR of breast
cancer cells to cytotoxic drugs has been linked to the
over-expression of cell-surface P-gp, with more than 40%
of breast cancers over-expressing P-gp [12]. P-gp is a
member of the adenosine triphosphate (ATP)-dependent
transporters that are known to confer cross-resistance to
a variety of structurally unrelated cytotoxic drugs, such as
anthracycline, taxanes, vinca alkaloids and other drugs
widely used for cancer treatment [13-15]. Based upon
these findings, we chose to investigate the effects of P-gp
substrate (ADM, VCR and Taxol) and P-gp non-substrate
(BLM) drugs on the survival of MDR1 and HA117 trans-
ducted cells.
ATRA, been a differentiation-inducing chemothera-
peutic agent, is widely used for the treatment of acute
promyelocytic leukemia (APL) and acute myeloid leuke-
mia (AML), and often induces complete remission in
most APL and AML patients [16-18]. However, clinical
experience has shown that patients treated with ATRA
alone does not remain on long-term remission and can in
fact develop ATRA-resistant APL or AML [19]. The exact
mechanism of ATRA resistance is still unknown,
although many researchers have reported that resistance
is caused by a point mutation in the PML/RARα fusion
gene or by up-regulation of meningioma-1 gene (MN1)
[20-22]. To elucidate the mechanism underlying ATRA
resistance, we examined the gene library of ATRA-resis-
tant HL-60 cells by suppressive subtractive hybridization
and discovered the novel gene HA117, which is associ-
ated with ATRA resistance in HL-60 cells and MDR in
both HL-60 and K562 cells. In the present study, we
transducted recombinant adenoviral vectors encoding
HA117 or MDR1 into breast cancer cell line 4T1 to inves-
tigate the MDR mechanism of HA117 and to perform a
Figure 6 Drug-elimination activity of HA117 and MDR1 as ana-
lyzed using the DNR efflux assay. The fluorescence intensity of DNR 
in 4T1/MDR1 cells (C) was much lower than that of 4T1 (A) and 4T1/
HA117 (B) cells (P < 0.05). There was no statistically significant differ-
ence in the DNR fluorescence intensity between 4T1 and 4T1/HA117 
cells (P > 0.05). The bar graphs represent the quantification and com-
parison of the fluorescence intensity of the cells. P > 0.05* vs. control 
cells (4T1), P < 0.05 ** vs. control cells (4T1). R1: Percent of all cells. R2: 
Percent of cells with no or low DNR fluorescence. This experiment was 
repeated at least 3 times with the same results.
Table 1: IC50 (μg/ml) for ADM, VCR, Taxol and BLM in 4T1, 4T1/HA117, 4T1/MDR1 and 4T1/GFP cells.
ADM VCR Taxol BLM
Cell lines IC50 (μg/ml) R.I. IC50 (μg/ml) R.I. IC50 (μg/ml) R.I. IC50 (μg/ml) R.I.
4T1 0.4159 ± 0.0791 1 0.4775 ± 0.0757 1 0.0294 ± 0.0058 1 0.4789 ± 0.1104 1
4T1/HA117 **8.2369 ± 1.9458 19.8050 **4.3292 ± 0.4452 9.0663 **0.2859 ± 0.0479 9.7245 *1.7073 ± 0.4062 3.5650
4T1/MDR1 **10.0746 ± 1.0684 24.2236 **5.2754 ± 1.0974 11.0480 **0.3050 ± 0.1067 10.3741 0.4612 ± 0.0733 0.9630
4T1/GFP 0.5126 ± 0.1547 1.2325 0.4508 ± 0.1193 0.9441 0.0292 ± 0.0016 0.9932 0.4924 ± 0.1172 1.0282
Values are shown as the mean ± SD.
ADM: Adriamycin; VCR: vincristine; Taxol: paclitaxel; BLM: bleomycin. * P < 0.05 and ** P < 0.01 compared to the respective control group.Zhao et al. Journal of Experimental & Clinical Cancer Research 2010, 29:98
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comparative study between HA117 and MDR1 in a solid
tumor cell line.
Here, we transducted adenoviral vectors containing the
GFP and HA117 genes or the GFP and MDR1 genes into
4T1 cells to generate the transductants 4T1/HA117 and
4T1/MDR1. The transduction efficiency and MOI were
analyzed by fluorescence microscope and flow cytometry.
Our results showed that the efficiency of transduction in
4T1 cells increased with increased concentration of the
adenovirus; however, the number of dead cells increased
when the MOI exceeded 50. Therefore, an MOI = 50 was
chosen for further experiments. We found that transduc-
tion of 4T1 cells with HA117 or MDR1 significantly
increased the transcription levels of both genes. We also
evaluated the sensitivity of stable transductants to P-gp
substrate (ADM, VCR, Taxol) and non-substrate (BLM)
drugs. The results of the MTT assay revealed that MDR
to P-gp substrate drugs was significantly enhanced in
HA117- and MDR1-expressing cells when compared to
their respective controls. There were no statistically sig-
nificant differences in the IC50 or the RI of ADM, VCR,
and Taxol between 4T1/HA117 and 4T1/MDR1 cells (P >
0.05), which indicates that the multidrug resistance
strength of HA117 is similar to that of MDR1. It is clear
that HA117 is a strong multidrug resistant novel gene and
much importance should be given to it. In addition, the
chemo-sensitivity of MDR1 transductants to the P-gp
non-substrate drug BLM remained unchanged but
decreased in HA117 transductants. This result is consis-
tent with the results of the DNR efflux assay which dem-
onstrated that the differences in the DNR fluorescence
intensity between 4T1/HA117 and 4T1 cells were not sta-
tistically significant (P > 0.05), whereas the differences
between 4T1/MDR1 and 4T1 cells were significantly sig-
nificant (P < 0.05). These results suggest that HA117 has
no drug-excretion function and that it may not generate
MDR in breast cancer cells using the same mechanism as
MDR1. So far, the specific mechanism by which HA117
promotes MDR is still unclear. Therefore, additional
studies are required to determine the exact mechanism of
MDR of HA117 including its association with the prog-
nosis of AML and whether it can promote drug resistance
in tumor cells in vivo.
Conclusions
Our study confirms that transduction of HA117- or
MDR1-expressing recombinant adenoviruses into breast
cancer cells can increase the transcription of these genes
and confer the breast cancer cells drug resistance. More-
over, the drug resistance of HA117 is similar to that of
MDR1, which makes it clear that HA117 is a strong mul-
tidrug resistance related novel gene. Our results also
show that HA117-induced MDR does not involve an
increase in the efflux of cytotoxic compounds out of the
cells. Overall, our study provides further insights into the
nature of HA117 and highlights the importance of choos-
ing the appropriate chemotherapeutic drugs for the treat-
ment of cancer patients.
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